Immunogenicity, safety, and antiphospholipid antibodies after SARS-CoV-2 vaccine in patients with primary antiphospholipid syndrome.
Flavio SignorelliGustavo Guimarães Moreira BalbiNádia Emi AikawaClovis Artur Almeida da SilvaLéonard de Vinci Kanda KupaAna C Medeiros-RibeiroEmily Fn YukiSandra Gofinet PasotoCarla Gs SaadEduardo Ferreira BorbaLuciana Parente Costa SeguroTatiana PedrosaVitor Antonio de Angeli OliveiraAna Luisa Cerqueira de Sant'Ana CostaCarolina T RibeiroRoseli Eliana Beseggio SantosDanieli Castro de Oliveira AndradeEloisa S BonfaPublished in: Lupus (2022)
We provided novel evidence that Sinovac-CoronaVac has high immunogenicity and safety profile in PAPS. Furthermore, Sinovac-CoronaVac did not trigger thrombosis nor induced changes in aPL production.